FDA Recalls Nearly 300,000 Dabigatran Blood Thinner Capsules: What Patients Should Know

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall involving nearly 300,000 capsules of dabigatran etexilate, a prescription blood thinner used to help prevent dangerous blood clots and reduce the risk of stroke in certain patients.

According to the FDA recall information, Alkem Laboratories Ltd. of Mumbai, India, voluntarily recalled three lots of dabigatran etexilate capsules because testing found impurity and degradation levels that exceeded established specifications. The affected medicine was distributed nationwide by Major Pharmaceuticals of Indianapolis.

The recall involves 299,520 capsules packaged in 5,460 cartons. Patients who take dabigatran or have recently received a prescription should check their medication packaging and speak with a pharmacist or physician if they believe their medicine could be part of the affected lots.

Why Was Dabigatran Recalled?

The FDA report states that the manufacturer identified a problem involving impurity and degradation specifications during stability testing.

Testing conducted at the 12-month point found levels of Impurity II, Impurity III, and total impurities above acceptable specifications. As a result, three lots were voluntarily recalled.

The affected lot numbers are:

• 25141583
• 25141585
• 25141586

All three lots have an expiration date of April 30, 2027.

The recalled products include different package sizes and strengths. The recall covers 150 mg capsules in 60-count blister packs, as well as 75 mg capsules supplied in both 60-count and 30-count blister packs.

Patients should not assume that every dabigatran product is affected. The recall specifically identifies the lots listed above, so checking the lot number on the medication packaging is important.

What Is Dabigatran Used For?

Dabigatran is an anticoagulant, commonly described as a blood thinner. It works by interfering with the body's ability to form blood clots.

The medication is used for several conditions in which preventing or treating blood clots is important. These include certain patients with atrial fibrillation, as well as people receiving treatment or prevention for deep vein thrombosis (DVT) and pulmonary embolism (PE).

Dabigatran may also be used to help prevent blood clots following certain surgical procedures, including hip replacement.

The drug is associated with the brand name Pradaxa and belongs to a group of medicines known as direct oral anticoagulants.

Why Blood Thinners Matter

Blood clots can become serious when they block blood flow to important organs. A clot that travels to the lungs can cause a pulmonary embolism, while a clot that affects blood flow to the brain can contribute to a stroke.

For people with certain heart rhythm conditions, including atrial fibrillation, anticoagulant medication can play an important role in reducing the risk of stroke.

Dabigatran gained attention after its FDA approval in 2010 as one of the early direct oral anticoagulants offered as an alternative to warfarin. One distinction between the medications is that patients taking warfarin generally require regular blood testing to monitor its effects.

However, all anticoagulants require careful use. Changing the dose, skipping medication, or abruptly stopping treatment can create significant health risks for some patients.

What Should Patients Do About the Recall?

The FDA advises patients not to stop taking a blood thinner abruptly without first speaking with a health care professional.

Anyone who believes they may have one of the recalled products should contact a physician or pharmacist. A health professional can determine whether the medication is affected by the recall and, if necessary, recommend an appropriate alternative.

Patients should have the medication container available when contacting their pharmacist because the product name, strength, lot number, and expiration date can help determine whether the medicine is included in the recall.

People taking anticoagulants should also avoid making medication changes based solely on reports about a recall. The risks associated with stopping an anticoagulant can vary depending on the individual's medical condition and treatment plan.

Dabigatran Has Been Recalled Before

This is not the first recall involving dabigatran.

In March 2023, Ascend Laboratories announced a voluntary nationwide recall involving certain generic dabigatran etexilate capsules. That action was associated with elevated levels of N-Nitroso-dabigatran, a type of nitrosamine impurity.

Nitrosamines can occur naturally or through environmental exposure, including in certain foods and water. The FDA has previously warned that prolonged exposure to nitrosamines above acceptable levels may potentially increase cancer risk.

The 2026 recall described in the FDA report is related to different impurity and degradation findings. Consumers should therefore rely on the specific FDA recall information and their medication's lot number rather than assuming that all dabigatran products have been recalled.

What Does the Recall Mean for Consumers?

A drug recall does not necessarily mean that every package of a medication is unsafe. Recalls can be limited to particular manufacturers, lots, strengths, or packaging configurations.

In this case, the FDA identifies three specific lots of dabigatran etexilate capsules manufactured by Alkem Laboratories. The recalled products were distributed nationwide by Major Pharmaceuticals.

Consumers who take dabigatran should check their packaging and consult a pharmacist or physician if they have questions. Health professionals can provide guidance on whether a particular prescription is affected and whether a replacement is needed.

Patients should also continue following their prescribed treatment plan unless their health care provider advises otherwise.

The Bottom Line

The FDA has announced a recall involving 299,520 dabigatran capsules because stability testing found impurity and degradation levels above specified limits. The affected products are associated with three lot numbers: 25141583, 25141585, and 25141586.

Because dabigatran is prescribed to help prevent serious blood-clot-related complications, patients should not discontinue the medication on their own. Anyone who may have an affected product should contact a pharmacist or physician for guidance and ask whether an alternative prescription is necessary.

The latest FDA recall information should be used to verify whether a specific medication is affected.

Sources

• U.S. Food and Drug Administration, drug recall information for the affected dabigatran etexilate products
• U.S. Food and Drug Administration, safety information concerning the 2023 dabigatran recall and nitrosamine impurities
• Mayo Clinic, information about dabigatran and its medical uses.
• Centers for Disease Control and Prevention, information concerning blood clots and recurrence risk.

Disclaimer

This article is intended for general informational and educational purposes only. It is not medical advice, a diagnosis, or a substitute for consultation with a qualified health care professional. Patients taking dabigatran or another anticoagulant should not stop, change, or replace their medication without speaking with their doctor or pharmacist. Always verify recall information with the FDA, your pharmacist, or your prescribing health care professional.